Description
Humana Press Inc. Target Discovery And Validation Reviews And Protocols by Mouldy Sioud
Target discovery is a field that has existed for several years but is so vibrant today because of the recent progress in our understanding of the molecular mechanisms of many human diseases and the technical advances in target identification and validation. More sophisticated gene profiling technologies, such as DNA microarrays and serial analysis of gene expression, permit rapid identification of lead targets. Moreover, analysis of gene networks in living organisms allows the identification of target genes that operate in defined physiological pathways. With the sequencing of several genomes completed and the rapidly growing gene expression databases, there is now greater impetus than ever before for in silico discovery of therapeutic targets. Also, recent advances in genetic technologies have increased our ability to generate mouse models for human diseases. The implications of these genetically modified animals in drug development are several, including identification of new drug targets, predicting efficacy, and uncovering possible side effects. Together, these recent technical advances should allow researchers to make the most informed choice early and advance the chosen targets toward clinical studies. Regarding cancers, any difference between a cancer and a normal cell could potentially be exploited as a therapeutic target. The hope is that drugs targeting specific constituents or pathways in cancer cells will provide more effective therapy, either alone or in combination with other currently used anticancer drugs. In addition to drug targets, identifying new target antigens remains as much of a challenge as improving tumor vaccines already in the clinic._x000D_ _x000D_
Target Discovery and Validation: Reviews and Protocols_x000D_
_x000D_
Part I: Emerging strategies for targets and biomarker discovery _x000D_
1. Main approaches to target discovery and validation_x000D_
Mouldy Sioud_x000D_
2. Bioinformatics approaches to cancer gene discovery_x000D_
Ramaswamy Narayanan_x000D_
3. Analysis of gene networks for drug target discovery and validation_x000D_
Seiya Imoto, Yoshinori Tamada, Christopher J. Savoie, and Satoru Miyano_x000D_
4. Target discovery and validation in pancreatic cancer_x000D_
Robert M. Beaty, Mads Gronborg, Jonathan R. Pollack, and Anirban Maitra_x000D_
5. Molecular classification of breast tumors: Clinical impact on diagnosis, prognosis, and treatment _x000D_
Therese Sorlie_x000D_
6. Discovery of differentially expressed genes: Technical considerations_x000D_
Oystein Rosok and Mouldy Sioud _x000D_
7. Genome-wide screening using siRNA-expression libraries_x000D_
Sahohime Matsumoto, Makoto Miyagishi, Ryozo Nagai, and Kazunari Taira_x000D_
8. Hammerhead ribozyme-based target discovery_x000D_
Masayuki Sano and Kazunari Taira_x000D_
9. Production of siRNA and cDNA transfected cell arrays on non-coated chambered coverglass for high content screening microscopy in living cells_x000D_
Holger Erfle and Rainer Pepperkok_x000D_
10. Transgenic animal models in biomedical research _x000D_
Louise-Marie Houdebine_x000D_
11. Keratin transgenic and knockout mice: Functional analysis and validation of disease-causing mutations_x000D_
Preethi Vijayaraj, Goran Soehl, and Thomas M. Magin_x000D_
12. The HUVEC/Matrigel assay - an in vivo assay of human angiogenesis suitable for drug validation_x000D_
Dag K. Skovseth, Axel M. Kuchler, and Guttorm Haraldsen_x000D_
13. A murine model for studying hematopoiesis and immunity in heart failure_x000D_
Per Ole Iversen and Dag R. Sorensen_x000D_
14. An overview of the immune system and technical advances in tumor antigen discovery _x000D_
Mouldy Sioud_x000D_
15. Potential target antigens for immunotherapy identified by serological expression cloning(SEREX)_x000D_
Dirk Jager_x000D_
16. Identification of tumor antigens using proteomics_x000D_
Francoise Le Naour_x000D_
17. Protein arrays: a versatile toolbox for target identification and monitoring of patient immune responses_x000D_
Lina Cekaite, Eivind Hovig and Mouldy Sioud_x000D_
18. Considerations for target validation and industrial approaches_x000D_
Carlos R. Plata-Salaman, and Sergey E. Ilyin_x000D_